| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |